Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

107 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Time-course changes in liver functional reserve after successful sofosbuvir/velpatasvir treatment in patients with decompensated cirrhosis.
Atsukawa M, Tsubota A, Kondo C, Toyoda H, Nakamuta M, Takaguchi K, Watanabe T, Hiraoka A, Uojima H, Ishikawa T, Iwasa M, Tada T, Nozaki A, Chuma M, Fukunishi S, Asano T, Ogawa C, Abe H, Kato K, Hotta N, Shima T, Matsuura K, Mikami S, Tachi Y, Fujioka S, Okubo H, Shimada N, Tani J, Morishita A, Hidaka I, Moriya A, Tsuji K, Akahane T, Okubo T, Arai T, Kitamura M, Morita K, Kawata K, Tanaka Y, Kumada T, Iwakiri K; KTK49 Liver Study Group. Atsukawa M, et al. Among authors: uojima h. Hepatol Res. 2022 Mar;52(3):235-246. doi: 10.1111/hepr.13739. Epub 2021 Dec 17. Hepatol Res. 2022. PMID: 34861090
Endoscopic Papillary Balloon Dilation Can Be Safely Performed in Patients on Dual Antiplatelet Therapy: A Pilot Study.
Masuda S, Jinushi R, Koizumi K, Makazu M, Nishino T, Shionoya K, Kimura K, Sumida C, Kubota J, Ichita C, Sasaki A, Kobayashi M, Kako M, Uojima H, Sugitani A. Masuda S, et al. Among authors: uojima h. J Gastrointestin Liver Dis. 2023 Jun 22;32(2):216-221. doi: 10.15403/jgld-4764. J Gastrointestin Liver Dis. 2023. PMID: 37345612 Free article.
Late Relapse after a Sustained Virologic Response at 24 Weeks after Treatment with Daclatasvir and Asunaprevir Combination Therapy for Chronic Hepatitis C Virus Genotype 1b Infection with Liver Cirrhosis.
Uojima H, Murakami S, Nakatani S, Hidaka H, Takeuchi A, Tanaka Y, Inoue T, Yamane K, Kubota K, Nakazawa T, Shibuya A, Tanaka Y, Koizumi W. Uojima H, et al. Intern Med. 2018 Apr 1;57(7):951-956. doi: 10.2169/internalmedicine.9671-17. Epub 2017 Dec 8. Intern Med. 2018. PMID: 29225269 Free PMC article.
Real-world virological efficacy and safety of elbasvir and grazoprevir in patients with chronic hepatitis C virus genotype 1 infection in Japan.
Toyoda H, Atsukawa M, Takaguchi K, Senoh T, Michitaka K, Hiraoka A, Fujioka S, Kondo C, Okubo T, Uojima H, Tada T, Yoneyama H, Watanabe T, Asano T, Ishikawa T, Tamai H, Abe H, Kato K, Tsuji K, Ogawa C, Shimada N, Iio E, Deguchi A, Itobayashi E, Mikami S, Moriya A, Okubo H, Tani J, Tsubota A, Tanaka Y, Masaki T, Iwakiri K, Kumada T. Toyoda H, et al. Among authors: uojima h. J Gastroenterol. 2018 Dec;53(12):1276-1284. doi: 10.1007/s00535-018-1473-z. Epub 2018 May 8. J Gastroenterol. 2018. PMID: 29740665
Efficacy and safety of elbasvir/grazoprevir for Japanese patients with genotype 1b chronic hepatitis C complicated by chronic kidney disease, including those undergoing hemodialysis: A post hoc analysis of a multicenter study.
Atsukawa M, Tsubota A, Toyoda H, Takaguchi K, Kondo C, Okubo T, Hiraoka A, Michitaka K, Fujioka S, Uojima H, Watanabe T, Ikeda H, Asano T, Ishikawa T, Matsumoto Y, Abe H, Kato K, Tsuji K, Ogawa C, Shimada N, Iio E, Mikami S, Tanaka Y, Kumada T, Iwakiri K. Atsukawa M, et al. Among authors: uojima h. J Gastroenterol Hepatol. 2019 Feb;34(2):364-369. doi: 10.1111/jgh.14447. Epub 2018 Sep 14. J Gastroenterol Hepatol. 2019. PMID: 30144366
Efficacy and safety of ombitasvir/paritaprevir/ritonavir and ribavirin for chronic hepatitis patients infected with genotype 2a in Japan.
Atsukawa M, Tsubota A, Toyoda H, Takaguchi K, Nakamuta M, Watanabe T, Tada T, Tsutsui A, Ikeda H, Abe H, Kato K, Uojima H, Ikegami T, Asano T, Kondo C, Koeda M, Okubo T, Arai T, Iwashita-Nakagawa A, Itokawa N, Kumada T, Iwakiri K. Atsukawa M, et al. Among authors: uojima h. Hepatol Res. 2019 Apr;49(4):369-376. doi: 10.1111/hepr.13292. Epub 2019 Jan 2. Hepatol Res. 2019. PMID: 30485638
Relationship between response to lusutrombopag and splenic volume.
Uojima H, Arase Y, Itokawa N, Atsukawa M, Satoh T, Miyazaki K, Hidaka H, Sung JH, Kako M, Tsuruya K, Kagawa T, Iwakiri K, Horie R, Koizumi W. Uojima H, et al. World J Gastroenterol. 2018 Dec 14;24(46):5271-5279. doi: 10.3748/wjg.v24.i46.5271. World J Gastroenterol. 2018. PMID: 30581275 Free PMC article.
Risk factors for loss of skeletal muscle mass in patients with cirrhosis.
Sung JH, Uojima H, Hidaka H, Tanaka Y, Wada N, Kubota K, Nakazawa T, Shibuya A, Fujikawa T, Yamanoue H, Kako M, Koizumi W. Sung JH, et al. Among authors: uojima h. Hepatol Res. 2019 May;49(5):550-558. doi: 10.1111/hepr.13308. Epub 2019 Feb 1. Hepatol Res. 2019. PMID: 30623996
The efficacy and safety of glecaprevir plus pibrentasvir in 141 patients with severe renal impairment: a prospective, multicenter study.
Atsukawa M, Tsubota A, Toyoda H, Takaguchi K, Nakamuta M, Watanabe T, Michitaka K, Ikegami T, Nozaki A, Uojima H, Fukunishi S, Genda T, Abe H, Hotta N, Tsuji K, Ogawa C, Tachi Y, Shima T, Shimada N, Kondo C, Akahane T, Aizawa Y, Tanaka Y, Kumada T, Iwakiri K. Atsukawa M, et al. Among authors: uojima h. Aliment Pharmacol Ther. 2019 May;49(9):1230-1241. doi: 10.1111/apt.15218. Epub 2019 Mar 14. Aliment Pharmacol Ther. 2019. PMID: 30873651 Clinical Trial.
107 results